Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)
- PMID: 26802717
- DOI: 10.1016/j.ophtha.2015.08.031
Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)
Comment in
-
Reply.Ophthalmology. 2016 Feb;123(2):e16. doi: 10.1016/j.ophtha.2015.08.034. Ophthalmology. 2016. PMID: 26802718 No abstract available.
Comment on
-
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.Ophthalmology. 2015 Jan;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041. Epub 2014 Sep 13. Ophthalmology. 2015. PMID: 25227499 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources